Tag: $Merck

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental drug for flu prevention in its effort to diversify ahead of patent loss for its blockbuster cancer drug Keytruda.

Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda.

A new tweak to Medicare’s drug price negotiation program will allow Merck to squeeze more revenue out of its cancer blockbuster Keytruda. The question is whether it will be enough to make a difference for the troubled stock.

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline.

Merck will buy UK-based Verona Pharma (NASDAQ:VRNA) for about $10 billion, the companies said on Wednesday, strengthening the U.S. drugmaker’s respiratory treatments as part of efforts to reduce dependence on its blockbuster cancer treatment.

Merck announces that the US FDA has approved Keytruda (pembrolizumab) for the treatment of adult patients with locally advanced head and neck squamous cell carcinoma (HNSCC) that is resectable and PD-L1-expressing.

The U.S. Food and Drug Administration on Monday approved Merck (NSE:PROR)’s preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said.

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong fourth-quarter profit on sales of cancer drug Keytruda.

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion.

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda.

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.

Merck  stock fell early Monday after a rival pharmaceutical company said its cancer drug beat Merck’s Keytruda in a head-to-head trial.

Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug.

Merck & Co. Inc. announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.

Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.

 Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company’s shares up more than 2% before the bell.

The FDA approved a drug from Merck designed to treat a rare, progressive and life-threatening lung condition called pulmonary arterial hypertension.

Merck reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda and HPV vaccine Gardasil.